Lonza to Expand with Two Additional Manufacturing Suites in Switzerland
Introduction:
Lonza plans for the expansion of additional bioconjugation capabilities in Switzerland.
Features:
The expansion will introduce two versatile 1,200L manufacturing suites and related infrastructure to the existing bioconjugation facility in Visp, Switzerland, to support launch and commercial supply.
These new suites will cover approximately 2,000 square metres and effectively double the multipurpose capacity for bioconjugate production at launch and commercial scales.
The additional suites will enhance early phase clinical development and large-scale production capabilities for launch and commercial distribution, with the inclusion of drug product filling features. This investment builds on Lonza’s recent customer-specific bioconjugation expansion at the Visp facility.
The multi-customer suites are designed to handle increasingly complex and diverse manufacturing processes, supporting the production of antibody-drug conjugates (ADCs) and other bioconjugates advancing through the development pipeline.
By expanding the multipurpose bioconjugation capacity, this investment addresses market needs and provides a flexible, integrated solution for bioconjugate manufacturing.
The new capacity is expected to create around 200 jobs and be operational by 2028.
Specifications:
| Name: | Lonza |
| Type : | Expansion |
| Year : | 2028 |
